DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Aug 21, 2023

Keywords

ClinConnect Summary

This clinical trial, called the DUPIlumab Dose REDUCtion study, is looking at how effective it is to extend the time between doses of a medication called dupilumab for adults with well-controlled atopic eczema (also known as atopic dermatitis). Researchers want to find out if giving dupilumab every 2, 3, or 4 weeks works just as well for managing symptoms and improving quality of life, while also considering how much of the medication is present in the body.

To participate in this study, you must be an adult diagnosed with atopic eczema who is currently receiving dupilumab every 2 weeks and has well-controlled symptoms. Participants will be randomly assigned to one of the three dosing groups and will be monitored to see how their condition responds. The trial is currently recruiting individuals, and it's important to note that participants cannot start any new treatments for their eczema during the study. This trial aims to understand the best ways to manage treatment while potentially reducing costs for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The subject is an adult,
• • Has a diagnosis of AE,
• • Receives dupilumab 300 mg q2w for the treatment of AE,
• • Has controlled disease according to the Treat-to-Target criteria,
• • Agrees to the possibility that the dosage of dupilumab will be lowered,
• • Has voluntarily signed and dated an informed consent prior to any study related procedure.
• Exclusion Criteria:
• • The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.